Table 1.

Patient demographic and disease characteristics (N = 65)

Characteristicn (%)
Female sex26 (40)
Death during observation period34 (52.3)
Age >60y22 (33.8)
Monoclonal protein
    Bence Jones4 (6.2)
    IgA21 (32.3)
    IgG39 (60)
    IgG + IgA1 (1.5)
Refractory or relapsed*60 (92.3)
Duration of disease > 60 mos*18 (27.7)
Prior high-dose chemotherapy45 (69.2)
Subsequent therapy TCED25 (38.5)
Serum β2-microglobulin > 2.5 mg/L (n = 60)36 (60)
Plasma creatinine > 1.3 mg/dL (n = 60)2 (3.3)
Plasma calcium > 2.65 mmol/L (n = 60)0 (0)
Durie/Salmon stage III56 (86.2)
Plasma LDH > 240 units/L (n = 58)2 (3.4)
Hemoglobin < 9 mg/dL (n = 60)7 (11.7)
  • Abbreviations: TCED, thalidomide/cyclophosphamide/etoposide/dexamethasone; LDH, lactate dehydrogenase.

  • * At time of DCE-MRI.

  • Upper level of normal controls for selected laboratory tests: serum β2-microglobulin (2.5 mg/L), plasma lactate dehydrogenase (240 units/L), plasma calcium (2.65 mmol/L), plasma creatinine (1.3 mg/dL).